| scholarly article | Q13442814 |
| P50 | author | Nebojsa Arsenijevic | Q47155565 |
| Ivan P Jovanovic | Q56997852 | ||
| Milica Milovan Borovcanin | Q47155558 | ||
| Jelena Pantic | Q47155562 | ||
| Gordana Radosavljevic | Q47155564 | ||
| P2093 | author name string | Miodrag L Lukic | |
| Slavica Minic Janicijevic | |||
| P2860 | cites work | Serum cytokine concentrations in patients with schizophrenia | Q71506011 |
| Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders | Q72031563 | ||
| Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness | Q72679203 | ||
| Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55 | Q72690586 | ||
| Elevated interleukin-6 in schizophrenia | Q73222786 | ||
| Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype | Q73509362 | ||
| Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects | Q73933538 | ||
| Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics | Q74233692 | ||
| Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia | Q80024902 | ||
| The facts of schizophrenia: a personal commentary | Q83766661 | ||
| Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients | Q84013033 | ||
| Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance | Q84707922 | ||
| Ingested (oral) tocilizumab inhibits EAE | Q87915233 | ||
| Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease | Q34431511 | ||
| Psychoneuroimmunology or immunopsychiatry? | Q34493614 | ||
| Gastrointestinal inflammation and associated immune activation in schizophrenia. | Q34574957 | ||
| Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. | Q34590921 | ||
| Gut microbiome, obesity, and metabolic dysfunction | Q34629745 | ||
| TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology | Q34712326 | ||
| Metabolic and inflammatory genes in schizophrenia | Q34769260 | ||
| Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis | Q34942662 | ||
| The two faces of IL-6 on Th1/Th2 differentiation | Q34996767 | ||
| IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii | Q35058854 | ||
| Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway. | Q35162796 | ||
| Genomics of schizophrenia: time to consider the gut microbiome? | Q35307203 | ||
| Lymphocytes as a neural probe: potential for studying psychiatric disorders | Q35749575 | ||
| Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis | Q35950801 | ||
| Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. | Q35968008 | ||
| The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia | Q36024597 | ||
| Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study | Q36032535 | ||
| Rapid linkage of innate immunological signals to adaptive immunity by the brain-fat axis | Q36041841 | ||
| Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. | Q36045153 | ||
| Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection | Q36055984 | ||
| Is there a role for immune-to-brain communication in schizophrenia? | Q36351021 | ||
| Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells | Q36376543 | ||
| Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer | Q36404654 | ||
| The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. | Q36408212 | ||
| Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication | Q36700322 | ||
| Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review | Q37001984 | ||
| Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin | Q37060706 | ||
| Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials | Q37228346 | ||
| Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta | Q37280573 | ||
| The influence of leptin on the dopamine system and implications for ingestive behavior. | Q37520621 | ||
| Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. | Q37541981 | ||
| Interleukin-6 signaling drives fibrosis in unresolved inflammation | Q37572817 | ||
| Development of DSM-V and ICD-11: tendencies and potential of new classifications in psychiatry at the current state of knowledge | Q37605220 | ||
| Epidemiology-driven neurodevelopmental animal models of schizophrenia. | Q37621632 | ||
| Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression | Q47215845 | ||
| The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. | Q47741981 | ||
| The expressions of mRNAs for interleukin-6 (IL-6) and the IL-6 receptor (IL-6R) in the rat hypothalamus and midbrain during restraint stress | Q47893353 | ||
| Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients | Q47965814 | ||
| A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression | Q48063321 | ||
| Interleukin-1 immunoreactive innervation of the human hypothalamus | Q48088092 | ||
| Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. | Q48139231 | ||
| Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. | Q48220306 | ||
| Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats | Q48478301 | ||
| Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. | Q48612749 | ||
| Regulatory T cells suppress sickness behaviour development without altering liver injury in cholestatic mice | Q48821129 | ||
| Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes | Q49049474 | ||
| Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. | Q50661690 | ||
| Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. | Q50743494 | ||
| Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. | Q50773766 | ||
| Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. | Q51100774 | ||
| Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. | Q51887161 | ||
| Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. | Q51981236 | ||
| Soluble factor(s) from LPS-activated macrophages induce cytotoxic T cell differentiation from alloantigen-primed spleen cells. | Q52228983 | ||
| Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. | Q53602998 | ||
| Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: Authors' reply. | Q53759693 | ||
| In vivo immunomodulatory effects of clozapine in schizophrenia | Q56767408 | ||
| Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10 | Q56930023 | ||
| Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype | Q57513593 | ||
| Cytokine profiles in drug-naive schizophrenic patients | Q57997579 | ||
| Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis | Q59326208 | ||
| Intracerebroventricular interleukin-6 treatment decreases body fat in rats | Q59649473 | ||
| Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Productionin Vitro | Q60632247 | ||
| Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25- T Cells | Q62658842 | ||
| Family history of type 2 diabetes in schizophrenic patients | Q69367752 | ||
| Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures | Q70147597 | ||
| Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation | Q37622623 | ||
| IL-6: regulator of Treg/Th17 balance | Q37768101 | ||
| Anti-inflammatory signaling in schizophrenia | Q37888032 | ||
| Immunological treatment options for schizophrenia | Q37979288 | ||
| The cellular and signaling networks linking the immune system and metabolism in disease | Q37991199 | ||
| Interleukin-6, a major cytokine in the central nervous system | Q38058511 | ||
| Neuroprotective effects of leptin in the context of obesity and metabolic disorders | Q38208135 | ||
| Interleukin-6 as a therapeutic target | Q38318758 | ||
| Transforming growth factor-beta enhances and pro-inflammatory cytokines inhibit ob gene expression in 3T3-L1 adipocytes | Q38341634 | ||
| IL-6 as a keystone cytokine in health and disease | Q38433045 | ||
| Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis | Q38981510 | ||
| Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables | Q39166258 | ||
| Factor analysis of risk variables associated with low-grade inflammation | Q40127876 | ||
| Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma | Q40624612 | ||
| Role of interleukin 6 in fever in rats | Q40764333 | ||
| Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene | Q41349604 | ||
| T-cell recruitment and Th1 polarization in adipose tissue during diet-induced obesity in C57BL/6 mice | Q41560139 | ||
| Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine | Q42283978 | ||
| Th1, Th2 and Th3 cytokine alteration in schizophrenia | Q42472093 | ||
| Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients | Q43185085 | ||
| Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice | Q43243138 | ||
| Interleukin-6-deficient mice develop mature-onset obesity | Q43851625 | ||
| Noradrenaline acting on astrocytic β₂-adrenoceptors induces neurite outgrowth in primary cortical neurons | Q44524644 | ||
| The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia | Q44766600 | ||
| Clinical effects of COX-2 inhibitors on cognition in schizophrenia. | Q45153924 | ||
| Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response | Q45169191 | ||
| Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness | Q45197223 | ||
| Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway | Q45329206 | ||
| Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine | Q45372399 | ||
| Interleukin-1 beta and tumor necrosis factor-alpha synergistically stimulate nerve growth factor (NGF) release from cultured rat astrocytes | Q46167645 | ||
| Molecular cloning and expression of an IL-6 signal transducer, gp130 | Q24328945 | ||
| Viruses, schizophrenia, and bipolar disorder | Q24669648 | ||
| Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment | Q26781620 | ||
| Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models | Q27687241 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Obesity is associated with macrophage accumulation in adipose tissue | Q27860976 | ||
| Transforming growth factor-beta induces development of the T(H)17 lineage | Q28237370 | ||
| Putative neuroprotective agents in neuropsychiatric disorders | Q28279830 | ||
| Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor | Q28291157 | ||
| The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production | Q28293593 | ||
| Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment | Q28350052 | ||
| Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia | Q28397737 | ||
| Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 | ||
| Obesity induces a phenotypic switch in adipose tissue macrophage polarization | Q29547686 | ||
| Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function | Q29616104 | ||
| Type 2 diabetes as an inflammatory disease | Q29617184 | ||
| Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma | Q30574207 | ||
| Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls | Q33803377 | ||
| Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge | Q33843562 | ||
| Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume | Q33849008 | ||
| Cytokines and the brain: implications for clinical psychiatry | Q33900651 | ||
| Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice | Q34006674 | ||
| Functional specialization of interleukin-17 family members | Q34025860 | ||
| Role of the gut microbiota in immunity and inflammatory disease | Q34036490 | ||
| Inflammatory molecular signature associated with infectious agents in psychosis | Q34048637 | ||
| Stress in schizophrenia: an integrative view | Q34061090 | ||
| Effects of antipsychotic drugs on cytokine networks | Q34133802 | ||
| Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin | Q34166632 | ||
| The immune system and schizophrenia. An integrative view. | Q34194859 | ||
| Consensus development conference on antipsychotic drugs and obesity and diabetes | Q34293049 | ||
| Anti-inflammatory treatment in schizophrenia | Q34313482 | ||
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 221 | |
| P577 | publication date | 2017-11-06 | |
| P1433 | published in | Frontiers in Psychiatry | Q27723495 |
| P1476 | title | Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? | |
| P478 | volume | 8 |
| Q91647621 | Inflammation as the Potential Basis in Depression |
| Q100695930 | Protein kinase C eta is activated in reactive astrocytes of an Alzheimer's disease mouse model: Evidence for its immunoregulatory function in primary astrocytes |
| Q64232326 | The Effects of Exercise on IL-6 Levels and Cognitive Performance in Patients with Schizophrenia |
Search more.